Hypercalcemia: Treatment

Assessment Before Treatment

Step 1: IV Volume Expansion (All Cases — First Priority)

• Hypercalcemia invariably causes dehydration (osmotic diuresis, polyuria, natriuresis)
• Saline restores euvolemia, improves GFR, and promotes urinary calcium excretion (calciuresis via natriuresis)
• 4–6 L IV over the first 24 h may be required in severe cases; adjust rate based on cardiovascular and renal status (200–500 mL/hr as a general guide)
• Monitor cardiopulmonary status closely to avoid volume overload

• Block NKCC2 in the thick ascending limb → disrupt the paracellular electrochemical gradient for Ca²⁺ reabsorption
• Dose: 20–40 mg IV; must not be given until euvolemia is restored (will worsen hypovolemia and hypercalcemia if given early)
• Primary role: prevent/treat volume overload in patients with heart failure or renal insufficiency; not routinely recommended in normocardiac, normo-renal patients with malignancy-associated hypercalcemia, as they add little to saline alone

Step 2: Pharmacologic Agents

Bisphosphonates (Aminobisphosphonates) — Mainstay

• Mechanism: Bind hydroxyapatite in bone → induce osteoclast apoptosis → potent inhibition of bone resorption
• Onset: 1–2 days; calcium nadir at 4–7 days; effect lasts ~2–4 weeks
• Response rate: 60–90% normalization of serum calcium
• Zoledronic acid preferred over pamidronate for malignancy-associated hypercalcemia (superior efficacy, shorter infusion time)
• Caution: Can precipitate acute kidney injury; administer slowly; contraindicated (or dose-adjusted) when GFR < 35 mL/min/1.73 m²

Calcitonin — For Rapid, Bridge Therapy

• Dose: 4–8 IU/kg SC or IM every 6–12 h
• Mechanism: Inhibits osteoclast-mediated bone resorption + enhances renal calcium excretion
• Onset: 2–4 hours (fastest of all agents — bridges the gap while bisphosphonates take effect)
• Limitation: Tachyphylaxis develops within 48–72 hours, limiting utility beyond 3 days
• Best used in the first 24–48 h concurrently with bisphosphonates in severe/symptomatic cases; may cause hypersensitivity reactions

Denosumab — For Bisphosphonate-Refractory or Renal Failure Patients

• Dose: 120 mg SC on days 1, 8, 15, and 29, then monthly; lower doses (0.3 mg/kg) used in advanced CKD
• Mechanism: Humanized monoclonal antibody against RANKL → inhibits osteoclast differentiation and function
• FDA-approved for hypercalcemia of malignancy refractory to bisphosphonates
• Key advantage: Cleared by the reticuloendothelial system (not the kidney) → safe in severe CKD/anuric renal failure where IV bisphosphonates are contraindicated
• Key risk: Severe hypocalcemia (especially in CKD) — monitor carefully

Glucocorticoids — For Vitamin D–Mediated Hypercalcemia

• Indications: Granulomatous diseases (sarcoidosis, TB, fungal infections), lymphoma, multiple myeloma, vitamin D toxicity
• Mechanism: Inhibit conversion of 25(OH)D → 1,25(OH)₂D in macrophages + reduce intestinal calcium absorption
• Regimens:
  • IV hydrocortisone 200–400 mg/day × 3–5 days (severe), or
  • Oral prednisone 40–60 mg/day × 7–14 days, with taper guided by calcium levels
• Not effective for PTH- or PTHrP-driven hypercalcemia

Cinacalcet — Calcimimetic (PTH-Driven Hypercalcemia)

• Mechanism: Allosteric activator of the calcium-sensing receptor (CaSR) → mimics higher Ca²⁺ → suppresses PTH secretion
• Dose: Start 30 mg twice daily; titrate to max 90 mg twice daily; take with food (reduces nausea)
• Indications:
  • Parathyroid carcinoma
  • Primary hyperparathyroidism (PHPT) patients not surgical candidates
  • Secondary hyperparathyroidism in dialysis patients
  • Combined with alendronate for PHPT can normalize calcium and improve bone density

Dialysis — Salvage for Severe/Refractory Cases

• Reserved for severe hypercalcemia with anuric acute kidney injury or congestive heart failure where saline hydration and bisphosphonates are not possible or too slow
• Effective calcium removal when other therapies are insufficient

Special Scenario: Primary Hyperparathyroidism (PHPT)

• Corrected Ca > 1.0 mg/dL above upper limit of normal
• Age < 50 years
• GFR < 60 mL/min
• T-score ≤ −2.5 or vertebral fracture on imaging
• 24-h urine calcium > 400 mg/day with increased stone risk, or nephrolithiasis/nephrocalcinosis on imaging
• Patient preference against observation

Summary Table